EVast Bio

EVast Bio is a biotechnology company specializing in the development of engineered extracellular vesicles (EVs), or exosomes, as a next-generation drug delivery platform. Based in Suzhou, China, the company focuses on overcoming the delivery challenges of nucleic acid drugs, such as mRNA, siRNA, and antisense oligonucleotides (ASOs), by leveraging the natural biocompatibility and targeting capabilities of exosomes. Their proprietary platform enables the precise loading and surface modification of EVs to treat a variety of conditions, including oncology and rare genetic disorders. EVast Bio aims to translate exosome science into clinical applications through a robust pipeline of therapeutic candidates currently in the pre-clinical stage. The company is supported by prominent venture capital firms and operates out of the Suzhou Industrial Park.